Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab N01 and Sintilimab in MSI-H/dMMR Gastric or GEJ Adenocarcinoma
NCT07878221Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial of ipilimumab and sintilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 cohorts), sponsored by Fudan University. Primary endpoints: Pathological Complete Response Rate and R0 Conversion Rate up to 24 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ipilimumabsintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07878221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07878221.